Table 2 Analysis of the factors influencing the postoperative prognosis of patients with giant cell tumor of the extremities
clinical parameters | total | Number of recurrence | Univariate analysis | multivariate analysis | ||
|---|---|---|---|---|---|---|
HR (95% CI) | p-value | Adjusted HR (95% CI) | p-value | |||
age (year) | 38.49 ± 11.10 | 30 | 1.00 (0.96~1.03) | 0.769 | 0.99 (0.95~1.03) | 0.541 |
sex | ||||||
 Male | 91 | 19 | 1.00 |  | 1.00 |  |
 Female | 72 | 11 | 0.68 (0.32~1.42) | 0.302 | 0.86 (0.39~1.93) | 0.717 |
Companacci stage | ||||||
 I-II stage | 86 | 6 | 1.00 |  | 1.00 |  |
 III stage | 77 | 24 | 5.95 (2.42~14.63) | < 0.001 | 3.28 (1.24~8.69) | 0.017 |
surgical method | ||||||
 expanded curettage | 94 | 17 | 1.00 |  |  |  |
 extensive resection | 69 | 13 | 1.15 (0.56~2.37) | 0.708 |  |  |
tumor diameter (cm) | 5 (4~7) | 30 | 1.12 (0.93~1.36) | 0.234 | Â | Â |
ALP(U/L) | 79 (63~122) | 30 | 1.01 (1.00~1.01) | 0.026 | 1.00 (0.99~1.00) | 0.284 |
white blood cell (109/L) | 6.03 (5.12~7.06) | 30 | 1.08 (0.84~1.39) | 0.539 | Â | Â |
ESR (mm/h) | 17 (9~34) | 30 | 1.01 (0.99~1.03) | 0.232 | Â | Â |
CRP (mg/L) | 8.16 (3.77~13.57) | 30 | 1.02 (1.01~1.03) | 0.004 | 1.02 (0.99~1.04) | 0.199 |
NLR | ||||||
 LNLR | 113 | 10 | 1.00 |  | 1.00 |  |
 HNLR | 50 | 20 | 5.90 (2.75~12.67) | < 0.001 | 4.18 (1.83~9.57) | 0.001 |
PLR | ||||||
 LPLR | 90 | 9 | 1.00 |  | 1.00 |  |
 HPLR | 73 | 21 | 3.17 (1.45~6.92) | 0.004 | 2.15 (0.90~5.14) | 0.084 |